Chemomab Therapeutics (CMMB) Non Operating Income (2017 - 2025)
Chemomab Therapeutics' (CMMB) quarterly Non Operating Income came in at -$101000.0 in Q4 2025, up 59.6% YoY from -$63283.2 in Q4 2024, and down 199.02% on a QoQ basis from $102000.0 in Q3 2025.
Chemomab Therapeutics (CMMB) Non Operating Income (2017 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 7 years of Non Operating Income data on file, last reported at -$101000.0 in Q4 2025.
- Quarterly Non Operating Income rose 59.6% year-over-year to -$101000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $370000.0 (up 25.85% YoY) and the FY2025 annual result came in at $572000.0, down 27.96% from the prior year.
- Non Operating Income declined to -$101000.0 in Q4 2025, from $102000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $480000.0 in Q2 2022 to a low of -$431000.0 in Q4 2023.
- A 4-year average of $29400.0 and a median of $137000.0 in 2024 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2024 — Non Operating Income jumped 198.27% — and 2025, when it sank 55.07%.
- Tracing CMMB's Non Operating Income over 4 years: stood at -$380000.0 in 2022, then fell by 13.42% to -$431000.0 in 2023, then soared by 42.0% to -$250000.0 in 2024, then surged by 59.6% to -$101000.0 in 2025.
- The last three Non Operating Income figures came in at -$101000.0 (Q4 2025), $102000.0 (Q3 2025), and $205000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -53.64 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -51.63 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Chemomab Therapeutics | 13.33 Mn | 2.96 Mn | - | -101,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -101,000.00 |
| Sep 30, 2025 | 102,000.00 |
| Jun 30, 2025 | 205,000.00 |
| Mar 31, 2025 | 164,000.00 |
| Dec 31, 2024 | -250,000.00 |
| Sep 30, 2024 | 227,000.00 |
| Jun 30, 2024 | 137,000.00 |
| Mar 31, 2024 | 180,000.00 |
| Dec 31, 2023 | -431,000.00 |
| Sep 30, 2023 | -231,000.00 |
| Jun 30, 2023 | 259,000.00 |
| Mar 31, 2023 | 317,000.00 |
| Dec 31, 2022 | -380,000.00 |
| Sep 30, 2022 | -237,000.00 |
| Jun 30, 2022 | 480,000.00 |
| Sep 30, 2019 | 12.45 Mn |
| Jun 30, 2019 | -2.77 Mn |
| Mar 31, 2019 | 12.87 Mn |
| Dec 31, 2018 | -1.33 Mn |
| Sep 30, 2018 | 60,000.00 |